The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients.
Xian WuChaoran YeXingmeng WangRuyu CaiJunzhe YangXiafei YuYi ZhouLi ShenYanhui ZhuXiaoan LiuPublished in: Cancer management and research (2021)
The efficacy of EC-P is better than EC-D if pCR is to be determined as a surrogate end-point for prognosis. The patients with anemia or renal insufficiency who need to receive NAC should choose EC-D.